Lilly's Mounjaro shows heart health benefits in head-to-head trial with Trulicity

The SURPASS-CVOT study met its primary objective by demonstrating that Mounjaro (tirzepatide) was non-inferior to Trulicity

Eli Lilly's dual GIP/GLP-1 drug, Mounjaro, has moved one step closer to receiving a cardiovascular risk reduction label following Phase 3 trial data showing that the therapy performed on par with the company's own GLP-1 predecessor, Trulicity, in a head-to-head study.

The SURPASS-CVOT study, which enrolled 13,299 patients across 30 countries with type 2 diabetes and established cardiovascular disease, met its primary objective by demonstrating that Mounjaro (tirzepatide) was non-inferior to Trulicity (dulaglutide) in reducing major adverse cardiovascular events (MACE-3), including cardiovascular death, heart attack and stroke.

"Cardiovascular disease remains the leading cause of death among people living with type 2 diabetes," said Kenneth Custer, Ph.D., executive vice president and president, Lilly Cardiometabolic Health. "The SURPASS-CVOT results show that Mounjaro preserved the cardioprotective benefit of Trulicity, a GLP-1 receptor agonist, while providing additional benefits, including greater kidney protection and a reduced overall risk of death. These findings strengthen the case for Mounjaro as a potential front-line treatment for people with type 2 diabetes and cardiovascular disease."